prostate cancer, sentinel node, lymph node, sentinel lymph node prostaat kanker, schildwachtklier, lymfeklier
Conditions
Interventions
On the morning of surgery patients will receive an transrectal-ultrasound guided intraprostatic or intratumoral injection with the hybrid tracer ICG-99mTc-nanocolloid. Thereafter, preoperative imaging
Sponsors
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Plesmanlaan 121
1066CX Amsterdam
The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: - patients >18 years of age - patients with histologically proven prostate cancer - patients with an increased risk of nodal metastasis according to the MSKCC nomogram (>10%) - scheduled for surgical (laparoscopic) prostatectomy including nodal dissection
Exclusion criteria
Exclusion criteria: - patients with a history of iodine allergy - patients with a hyperthyroid or thyroidal adenoma - patients with kidney insufficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Further validation of the sentinel node procedure for prostate cancer via an ultrasound-guided transrectal ICG-99mTc-nanocolloid. - Improve the intraoperative detection of the true tumor draining (tumor positive) sentinel nodes by improved injection techniques. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improve sentinel node dissection using combined radio- and fluorescence guidance after injection of the hybrid tracer and (in a subset of patients) a subsequent fluorescein injection prior to the start of the surgical procedure. | — |
Contacts
Public ContactH.G. Poel, van der
Department of Urology The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121
Outcome results
None listed